Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats. is a research paper published in Experimental and Clinical Psychopharmacology (2023). On theSindex it has a DataRank of 0. It has been cited 42 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: DA055879, DA044479, DA046526, DA049130, DA045881
National Institutes of Health
Grant: DA051377
National Institutes of Health
Grant: DA058933
NIDA NIH HHS
Grant: R01 DA058933
NIDA NIH HHS
Grant: R33 DA049130
NIDA NIH HHS
Grant: U01 DA051377
NIDA NIH HHS
Grant: R21 DA049130
NIDA NIH HHS
Grant: R21 DA044479
NIDA NIH HHS
Grant: R01 DA046526
NIDA NIH HHS
Grant: R21 DA055879
NIDA NIH HHS
Grant: R03 DA045881
Kentucky Medical Services Foundation
NIH HHS
Fields of Study
MeSH Terms